Cited by 130Cytokine Signaling Pathways and InteractionsCancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

The DOI matches its Crossref record; 201 of the 203 references it cites were found in a registry or an index.

STAT3, a Master Regulator of Anti-Tumor Immune Response

Open access

Rébé, Cédric, Ghiringhelli, François·2019·Cancers

DOI 10.3390/cancers11091280PMC PMC6770459

Open this paper in CoChat — free account Open PDF

Abstract

Immune cells in the tumor microenvironment regulate cancer growth. Thus cancer progression is dependent on the activation or repression of transcription programs involved in the proliferation/activation of lymphoid and myeloid cells. One of the main transcription factors involved in many of these pathways is the signal transducer and activator of transcription 3 (STAT3). In this review we will focus on the role of STAT3 and its regulation, e.g., by phosphorylation or acetylation in immune cells and how it might impact immune cell function and tumor progression. Moreover, we will review the ability of STAT3 to regulate checkpoint inhibitors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3390/cancers11091280

Cites

201 of 201 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3
Chen, W., Jin, W., Hardegen, N. J., Lei, K.-J., Li, L., Marinos, N. J., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,678
The Dendritic Cell System and its Role in Immunogenicity
Steinman, R. M. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001415 · Cited by 4,659
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M. J., Obenauf, A. C., Angell, H. K., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,455
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023

Show all 203 references

Sorted by citations

IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
“Furthermore, NF-κ B and STAT3 play crucial roles in cancer development and progression (19, 25, 67, 279).”
BackgroundInfluential
Targeting STAT3 in Cancer Immunotherapy
Zou, S., Tong, Q., Liu, B., Huang, W., Tian, Y., & Fu, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01258-7 · Cited by 1,109
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 410
Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside
Lizardo, D. Y., Kuang, C., Hao, S., Yu, J., Huang, Y., & Zhang, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188447 · Cited by 216
Microalgae with Immunomodulatory Activities
Riccio, G., & Lauritano, C. (2019) · Marine Drugs · doi:10.3390/md18010002 · Cited by 191
The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy
Garg, M., Shanmugam, M. K., Bhardwaj, V., Goel, A., Gupta, R., Sharma, A., Baligar, P., Kumar, A. P., Goh, B. C., Wang, L., et al. (2020) · Medicinal Research Reviews · doi:10.1002/med.21761 · Cited by 143
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
Besse, B., Tostivint, E. P., Park, K., Hartl, S., Forde, P. M., Hochmair, M. J., Awad, M. M., Thomas, M., Goss, G. D., Wheatley‐Price, P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02808-y · Cited by 144
Novel activators and small-molecule inhibitors of STAT3 in cancer
Yang, L., Lin, S., Xu, L., Lin, J., Zhao, C., & Huang, X. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.10.005 · Cited by 121
Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment
Piperi, C., Papavassiliou, K. A., & Papavassiliou, A. G. (2019) · Cells · doi:10.3390/cells8111398 · Cited by 120
Targeting STAT3 Signaling Pathway in Colorectal Cancer
Gargalionis, A. N., Papavassiliou, K. A., & Papavassiliou, A. G. (2021) · Biomedicines · doi:10.3390/biomedicines9081016 · Cited by 115
Icaritin‐induced immunomodulatory efficacy in advanced hepatitis B virus‐related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival
Qin, S., Li, Q., Xu, J., Liang, J., Cheng, Y., Fan, Y., Jiang, J., Ye, H., Tao, H., Li, L., et al. (2020) · Cancer Science · doi:10.1111/cas.14641 · Cited by 97
STAT3 blockade ameliorates LPS-induced kidney injury through macrophage-driven inflammation
Lee, S. H., Kim, K. H., Lee, S. M., Park, S., Lee, S., Cha, R., Lee, J. W., Kim, D. K., Kim, Y. S., Ye, S., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01841-1 · Cited by 89
RETRACTED: Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice
Bastaki, S., Surendar, A., Saheb, N. A., Kashani, M. A., Dorofeev, A. E., Kiani, F. K., Jahandideh, H., Dargani, F. B., Aksoun, M., Nikkhoo, A., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118847 · Cited by 83
Retracted
Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities
Parakh, S., Ernst, M., & Poh, A. R. (2021) · Cancers · doi:10.3390/cancers13246228 · Cited by 77
Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation
Lu, S., Sun, X., Zhou, Z., Tang, H., Xiao, R., Lv, Q., Wang, B., Qu, J., Yu, J., Sun, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1235575 · Cited by 68
Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy
Verdeil, G., Lawrence, T., Schmitt‐Verhulst, A., & Auphan‐Anezin, N. (2019) · Cancers · doi:10.3390/cancers11121832 · Cited by 64
Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models
Noonepalle, S. K. R., Shen, S., Ptáček, J., Tavares, M. T., Zhang, G., Stránský, J., Pavlı́ček, J., Ferreira, G. M., Hadley, M. M., Pelaez, G. D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00567 · Cited by 62
Inhibiting STAT3 signaling pathway by natural products for cancer prevention and therapy: In vitro and in vivo activity and mechanisms of action
Yang, J., Wang, L., Guan, X., & Qin, J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106357 · Cited by 61
STAT3/miR-135b/NF-κB axis confers aggressiveness and unfavorable prognosis in non-small-cell lung cancer
Zhao, J., Wang, X., Mi, Z., Jiang, X., Sun, L., Zheng, B., Wang, J., Meng, M., Zhang, L., Wang, Z., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03773-x · Cited by 59
Hypoxia-driven protease legumain promotes immunosuppression in glioblastoma
Pang, L., Guo, S., Khan, F., Dunterman, M., Ali, H. A., Liu, Y., Huang, Y.-Y., & Chen, P. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101238 · Cited by 59
Inflammatory Networks in Renal Cell Carcinoma
Kruk, L., Mamtimin, M., Braun, A., Anders, H., Andrassy, J., Gudermann, T. W., & Mammadova‐Bach, E. (2023) · Cancers · doi:10.3390/cancers15082212 · Cited by 59
Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposing
Dong, Y., Chen, J., Chen, Y., & Liu, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115513 · Cited by 59
Tumor-Associated Macrophages in Glioblastoma: Mechanisms of Tumor Progression and Therapeutic Strategies
Chen, J., Wu, Q., Berglund, A., Macaulay, R. J. B., Mulé, J. J., & Etame, A. B. (2025) · Cells · doi:10.3390/cells14181458 · Cited by 49
Tumor-Derived Extracellular Vesicles Enable Tumor Tropism Chemo-Genetherapy for Local Immune Activation in Triple-Negative Breast Cancer
Peng, Z., Zhao, T., Gao, P., Zhang, G., Wu, X., Tian, H., Qu, M., Tan, X., Zhang, Y., Zhao, X., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c12967 · Cited by 46
STAT3: A key signaling molecule for converting cold to hot tumors
Hu, R., Han, Q., & Zhang, J. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.035 · Cited by 45
Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives
Seif, F., Torki, Z., Zalpoor, H., Habibi, M., & Pornour, M. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.01.001 · Cited by 44
The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update
Merhi, M., Ahmad, F., Taib, N., Inchakalody, V. P., Shahab Uddin, M. S., Shablak, A., & Dermime, S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.01.001 · Cited by 41
Renal cancer: signaling pathways and advances in targeted therapies
Jiang, A., Li, J., He, Z., Liu, Y., Qiao, K., Fang, Y., Qu, L., Luo, P., Lin, A., & Wang, L. (2024) · MedComm · doi:10.1002/mco2.676 · Cited by 45
Transcriptional Regulation of Cancer Immune Checkpoints: Emerging Strategies for Immunotherapy
Venkatraman, S., Meller, J., Hongeng, S., Tohtong, R., & Chutipongtanate, S. (2020) · Vaccines · doi:10.3390/vaccines8040735 · Cited by 36
STAT3 and mutp53 Engage a Positive Feedback Loop Involving HSP90 and the Mevalonate Pathway
Romeo, M. A., Montani, M. S. G., Benedetti, R., Santarelli, R., D’Orazi, G., & Cirone, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01102 · Cited by 36
Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition
Singh, S., Gomez, H. J., Thakkar, S., Singh, S. P., & Parihar, A. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054722 · Cited by 38
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
Witt, K., Axelsson, S. E., Lundqvist, A., Johansson, M., Bjartell, A. S., & Hellsten, R. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02915-6 · Cited by 35
EZH2 Exacerbates Breast Cancer by Methylating and Activating STAT3 Directly
Zhao, Y., Hu, Z., Li, J., & Hu, T. (2021) · Journal of Cancer · doi:10.7150/jca.50675 · Cited by 35
Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression
Jin, J., Li, Y., Zhao, Q., Chen, Y., Fu, S., & Wu, J. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00705-2 · Cited by 37
RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors
Ganesh, S., Kim, M. J., Lee, J., Feng, X., Ule, K., Mahan, A. L., Krishnan, H. S., Wang, Z., Anzahaee, M. Y., Singhal, G., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.035 · Cited by 31
2′-Hydroxycinnamaldehyde ameliorates imiquimod-induced psoriasiform inflammation by targeting PKM2-STAT3 signaling in mice
Hao, L., Mao, Y., Park, J., Kwon, B., Bae, E. J., & Park, B. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00620-z · Cited by 27
Emphasis on Adipocyte Transformation: Anti-Inflammatory Agents to Prevent the Development of Cancer-Associated Adipocytes
Na, H., Song, Y., & Lee, H. (2023) · Cancers · doi:10.3390/cancers15020502 · Cited by 26
STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma
Ploeger, C., Schreck, J., Huth, T., Fraas, A., Albrecht, T., Charbel, A., Ji, J., Singer, S., Breuhahn, K., Pusch, S., et al. (2022) · Cancers · doi:10.3390/cancers14051154 · Cited by 27
Myeloid-derived suppressor cells and regulatory T cells in colorectal cancer: a synergistic immunosuppressive axis and emerging therapeutic opportunities
Zhang, W., Jin, C., Liu, S., Wan, X., Li, Y., Liu, J., Duan, Z., Ma, J., & Gao, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1757513 · Cited by 22
Inhibition of STAT3/PD-L1 and Activation of miR193a-5p Are Critically Involved in Apoptotic Effect of Compound K in Prostate Cancer Cells
Lee, J.-H., Lee, D., Lee, H., Im, E., Sim, D. Y., Park, J.-E., Park, W.-Y., Shim, B., & Kim, S. (2021) · Cells · doi:10.3390/cells10082151 · Cited by 21
RETRACTED ARTICLE: Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma
Peng, X., Yu, Z., Surineni, G., Deng, B., Zhang, M., Li, C., Sun, Z., Pan, W., Liu, Y., Liu, S., et al. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2201408 · Cited by 22
Retracted
Induction of immunogenic cell death and enhancement of the radiation-induced immunogenicity by chrysin in melanoma cancer cells
Jafari, S., Ardakan, A. K., Aghdam, E. M., Mesbahi, A., Montazersaheb, S., & Molavi, O. (2024) · Scientific Reports · doi:10.1038/s41598-024-72697-1 · Cited by 20
p53-regulated SESN1 and SESN2 regulate cell proliferation and cell death through control of STAT3
Haidurov, A., Zheltukhin, A. O., Snezhkina, A. V., Krasnov, G. S., Kudryavtseva, A. V., & Budanov, A. V. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02104-3 · Cited by 20
Design, Synthesis, and Biological Evaluation of Novel Quinazolin-4(3H)-one-Based Histone Deacetylase 6 (HDAC6) Inhibitors for Anticancer Activity
Khetmalis, Y. M., Fathima, A., Schweipert, M., Debarnot, C., Bandaru, N. V. M. R., Murugesan, S., Trinath, J., Meyer‐Almes, F., & Sekhar, K. V. G. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311044 · Cited by 19
The cross-talk between STAT1/STAT3 and ROS up-regulates PD-L1 and promotes the release of pro-inflammatory/immune suppressive cytokines in primary monocytes infected by HHV-6B
Romeo, M. A., Montani, M. S. G., Benedetti, R., Giambelli, L., D’Aprile, R., Gaeta, A., Faggioni, A., & Cirone, M. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198231 · Cited by 18
Targeting STAT3 and STAT5 in Cancer
de Araujo, E. D., Keserű, G. M., Gunning, P. T., & Moriggl, R. (2020) · Cancers · doi:10.3390/cancers12082002 · Cited by 17
A STAT3/integrin axis accelerates pancreatic cancer initiation and progression
Campos, A. D., Shepard, R. M., Ortega, Z. M., Heumann, I., Wilke, A. E., Nam, A., Cable, C., Kouhmareh, K., Klemke, R., Mattson, N. M., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116010 · Cited by 16
Mechanism of Action of Melatonin as a Potential Adjuvant Therapy in Inflammatory Bowel Disease and Colorectal Cancer
Jurjus, A. R., Masri, J. E., Ghazi, M., Ayoubi, L. M. E., Soueid, L., Geagea, A. G., & Jurjus, R. A. (2024) · Nutrients · doi:10.3390/nu16081236 · Cited by 18
TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications
Papadaki, M. A., Monastirioti, A. A., Apostolopoulou, C. A., Aggouraki, D., Papadaki, C., Michaelidou, K., Vassilakopoulou, M., Alexakou, K., Mavroudis, D., & Agelaki, S. (2022) · Cancers · doi:10.3390/cancers14041053 · Cited by 16
Coagulation Protease-Driven Cancer Immune Evasion: Potential Targets for Cancer Immunotherapy
Paul, S., Mukherjee, T., & Das, K. (2024) · Cancers · doi:10.3390/cancers16081568 · Cited by 16
Chuanxiong Rhizoma regulates ferroptosis and the immune microenvironment in ischemic stroke through the JAK-STAT3 pathway
Ge, Q., Wang, Z., Yu, J., Feng, X., Li, J., Zhang, X., Wang, S., Wang, L., & Chen, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-82486-5 · Cited by 15
Efficient polymeric nanoparticles for RNAi in macrophage reveal complex effects on polarization markers upon knockdown of STAT3/STAT6
Walther, M., Jenke, R., Aigner, A. M., & Ewe, A. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114232 · Cited by 14
Harnessing the capacity of phytochemicals to enhance immune checkpoint inhibitor therapy of cancers: A focus on brain malignancies
Afshari, A. R., Sanati, M., Ahmadi, S. S., Kesharwani, P., & Sahebkar, A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216955 · Cited by 14
Th17 cells in cancer: plasticity‐driven immunopathology and therapeutic opportunity
Sutanto, H., Ningtyas, M. C., Rachma, B., Pratiwi, L., & Fetarayani, D. (2025) · Immunology and Cell Biology · doi:10.1111/imcb.70043 · Cited by 16
8‐Epi ‐xanthatin induces the apoptosis of DU145 prostate carcinoma cells through signal transducer and activator of transcription 3 inhibition and reactive oxygen species generation
Lee, Y., Choi, J., Yoon, Y. J., Sim, Y., Ryu, H. W., Oh, S., Kim, D., Hwang, J.-H., Chi, S., Han, D. C., et al. (2020) · Phytotherapy Research · doi:10.1002/ptr.6918 · Cited by 12
STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma
Yamamoto, K., Ioroi, T., Shinomiya, K., Yoshida, A., Harada, K., Fujisawa, M., Omura, T., Ikemi, Y., Nakagawa, S., Yonezawa, A., et al. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504022x16418911579334 · Cited by 10
Paracrine Regulation and Immune System Pathways in the Inflammatory Tumor Microenvironment of Lung Cancer: Insights into Oncogenesis and Immunotherapeutic Strategies
Batrash, F., Shaik, A., Rauf, R., Kutmah, M., & Zhang, J. (2024) · Cancers · doi:10.3390/cancers16061113 · Cited by 11
Inhibition of STAT3: A promising approach to enhancing the efficacy of chemotherapy in medulloblastoma
Kumar, S., Arwind, D. A., Harish Kumar., B., Pandey, S., Nayak, R., Vithalkar, M. P., Kumar, N., & Pai, K. S. R. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102023 · Cited by 13
Glucocorticoid Receptor-Targeted Nanoliposome for STAT3 Inhibition-Led Myeloid-Derived Suppressor Cell Modulation and Efficient Colon Cancer Treatment
Bhattacharyya, T., Das, P., Ansari, A., Mohan, A. A., Chandra, Y., Narayan, K. P., & Banerjee‬‬‬‬‬‬‬‬‬, R. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00002 · Cited by 10
IL-17 induces NSCLC cell migration and invasion by elevating MMP19 gene transcription and expression through the interaction of p300-dependent STAT3-K631 acetylation and its Y705-phosphorylation
GE, W., Li, Y., RUAN, Y., Wu, N., Ma, P., Xu, T., Shu, Y., WANG, Y., Qiu, W., & Zhao, C. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.031053 · Cited by 10
Methylgerambullin Derived From Plant Glyccsmis Pentaphylla (Retz) Correa. Mediates Anti-Hepatocellular Carcinoma Cancer Effect by Activating Mitochondrial and Endoplasmic Reticulum Stress Signaling and Inhibiting AKT and STAT3 Pathways.
Wu, C., Shu, G.-W., Huang, H.-Q., Pang, K., Yang, X.-Z., & Yang, G.-Z. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112031 · Cited by 9
Intratumoural expression of IL-6/STAT3, IL-17 and FOXP3 immune cells in the immunosuppressive tumour microenvironment of colorectal cancerImmune cells-positive for IL-6, STAT3, IL-17 and FOXP3 and colorectal cancer development
Gulubova, M. V., Chonov, D. C., Ivanova, K. V., Hristova, M. K., Krasimirova-Ignatova, M. M., & Vlaykova, T. I. (2022) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2022.2072765 · Cited by 10
STAT activation in regulatory CD4+ T cells of patients with primary sclerosing cholangitis
Dold, L., Kalthoff, S., Frank, L., Zhou, T., Esser, P. L., Lutz, P. L., Strassburg, C. P., Spengler, U., & Langhans, B. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1248 · Cited by 9
At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma
Wondergem, N. E., Nijenhuis, D. N. L. M., Poell, J. B., Leemans, C. R., Brakenhoff, R. H., & van de Ven, R. (2021) · Frontiers in Oral Health · doi:10.3389/froh.2021.647980 · Cited by 9
Interferon-γ-mediated selective inhibition of hematopoiesis and the clonal advantage of HLA-lacking hematopoietic stem progenitor cells in aplastic anemia
Takahashi, R., Takahashi, H., Seoka, L., Iwasaki, H., Takamatsu, H., Imi, T., Zaimoku, Y., Hosokawa, K. T., & Katagiri, T. (2025) · Leukemia · doi:10.1038/s41375-025-02595-6 · Cited by 10
Potential value and mechanism of Rosa roxburghii tratt juice on pro-inflammatory responses in peripheral blood of patients with arsenic poisoning
Dong, L., Xia, S., Sun, B., Ma, L., Chen, X., Wei, S., Zou, Z., & Zhang, A. (2022) · Human & Experimental Toxicology · doi:10.1177/09603271221121313 · Cited by 8
Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting?
Stéphan, P., Lautraite, R., Voisin, A., & Grinberg‐Bleyer, Y. (2020) · Cancers · doi:10.3390/cancers12113194 · Cited by 10
IKBKE, a prognostic factor preferentially expressed in mesenchymal glioblastoma, modulates tumoral immunosuppression through the STAT3/PD‐L1 pathway
Li, Y., Guo, G., Li, J., Fan, X., Li, T., Tong, L., Liu, P., Wang, X., Yuan, F., Yu, S., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.130 · Cited by 7
Epstein-Barr virus infectious particles initiate B cell transformation and modulate cytokine response
Baccianti, F., Masson, C., Delécluse, S., Li, Z., Poirey, R., & Delecluse, H. (2023) · mBio · doi:10.1128/mbio.01784-23 · Cited by 7
A network pharmacology approach to elucidate the anti-inflammatory and antioxidant effects of bitter leaf (Vernonia amygdalina Del.)
Sailah, I., Tallei, T. E., Safitri, L., Tamala, Y., Halimatushadyah, E., Ekatanti, D., Maulydia, N. B., & Çeli̇k, İ. (2024) · Narra J · doi:10.52225/narra.v4i3.1016 · Cited by 8
Esketamine attenuates traumatic brain injury by modulating STAT3-mediated Glycolysis and immune responses
Liu, Y., Gong, Z., Zhang, L., Yang, X., Zhu, J., Zhou, X., & Liao, X. (2025) · BMC Neuroscience · doi:10.1186/s12868-025-00941-z · Cited by 7
A cohort study using IL-6/Stat3 activity and PD-1/PD-L1 expression to predict five-year survival for patients after gastric cancer resection
Li, X. N., Peng, Y. H., Yue, W., Lin, T., & Zhang, W. J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277908 · Cited by 7
Antitumor Activity of the Cardiac Glycoside αlDiginoside by Modulating Mcl-1 in Human Oral Squamous Cell Carcinoma Cells
Weng, J., Lin, W., Bai, L., Hu, J., & Feng, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217947 · Cited by 7
Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors
Lu, H., Teng, Z., Wang, J., & Zhang, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1583363 · Cited by 7
Comprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient
Bresadola, L., Weber, D., Ritzel, C., Löwer, M., Bukur, V., Akilli‐Öztürk, Ö., Becker, J., Mehanna, H. M., Schrörs, B., Vascotto, F., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147583 · Cited by 6
Companion Animals as Models for Inhibition of STAT3 and STAT5
Kieslinger, M., Swoboda, A., Kramer, N., Pratscher, B., Wolfesberger, B., & Burgener, I. A. (2019) · Cancers · doi:10.3390/cancers11122035 · Cited by 6
A New IL-6-Inducing Mechanism in Cancer with New Therapeutic Possibilities
Håkansson, L., Dunér, P., Broströmer, E., Gustavsson, B. G., Wettergren, Y., Ghafouri, B., Håkansson, A., & Clinchy, B. (2024) · Cancers · doi:10.3390/cancers16213588 · Cited by 6
VPS35/Retromer-dependent MT1-MMP regulation confers melanoma metastasis
Hao, Q., Bai, Y., Guan, R., Dong, R., Bai, W., Hamdy, H., Wang, L., Meng, M., Sun, Y., Shen, J., et al. (2025) · Science China Life Sciences · doi:10.1007/s11427-024-2884-2 · Cited by 6
The missing link? LGMN connects hypoxia and immunosuppression in glioblastoma
Mitchell, J., Colon, B., Bayık, D., & Lathia, J. D. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101293 · Cited by 5
Using bioinformatics and artificial intelligence to map the cyclin-dependent kinase 4/6 inhibitor biomarker landscape in breast cancer
Wager, K., Wang, Y., Liew, A. T. F., Campbell, D., Liu, F., Martini, J.-F., Ziaee, N., & Liu, Y. (2024) · Future Oncology · doi:10.1080/14796694.2024.2419352 · Cited by 6
Targeting STAT3 pathway: A promising immunotherapeutic strategy for triple-negative breast cancer – Current status and future outlooks
Malekinejad, Z., Aghdam, E. M., Ardakan, A. K., Forghan, E., Alizadeh, M., Simiyari, R., Heidari, H. R., & Montazersaheb, S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178079 · Cited by 7
Immune Subtype Profiling and Establishment of Prognostic Immune-Related lncRNA Pairs in Human Ovarian Cancer
Wang, X., Wang, J., & Yu, M. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/8338137 · Cited by 5
Retracted
Nifuroxazide in combination with CpG ODN exerts greater efficacy against hepatocellular carcinoma
Wang, Y., Liu, W., Liu, M., Wang, H., Zhou, L., Chen, J., Sun, H. X., Wei, X., Fan, M., Yang, M., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108911 · Cited by 5
Discovery of selective HDAC6 inhibitors capped by flavonoid or flavonoid-analogous moieties as anti-cancer therapeutics simultaneously harboring anti-proliferative and immunomodulatory activities
He, G., Li, Z., Zhang, M., Li, Z., Wang, Y., Zhao, F., Wang, Y., & Ma, X. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106146 · Cited by 5
Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through in vivo B cell knockout models
Hogan, C. H., Owens, S. M., Reynoso, G. V., Liao, Y., Meyer, T. J., Zelazowska, M. A., Liu, B., Li, X., Großkopf, A. K., Khairallah, C. F., et al. (2024) · mBio · doi:10.1128/mbio.02998-23 · Cited by 5
Immune Evasion in Cancer Is Regulated by Tumor-Asociated Macrophages (TAMs): Targeting TAMs
Jung, M., & Bonavida, B. (2024) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2024053096 · Cited by 5
Stat3 Regulates Developmental Hematopoiesis and Impacts Myeloid Cell Function via Canonical and Non-Canonical Modalities
Sobah, M. L., Liongue, C., & Ward, A. C. (2024) · Journal of Innate Immunity · doi:10.1159/000538364 · Cited by 4
Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL[30]-PEG[5K] for the RNAi-based therapy of breast cancer
Ye, Z., Abdelmoaty, M. M., Ambardekar, V. V., Curran, S. M., Dyavar, S. R., Arnold, L. L., Cohen, S. M., Kumar, D., Alnouti, Y., Coulter, D. W., et al. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102363 · Cited by 5
B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an in vivo competition modelPreprint
Hogan, C. H., Owens, S. M., Reynoso, G. V., Kirillov, V., Meyer, T. J., Zelazowska, M. A., Liu, B., Li, X., Chikhalya, A., Dong, Q., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.22.533727 · Cited by 5
A novel immunological perspective on female-specific cancers: Exploring the signaling pathways of tertiary lymphoid structures and their clinical applications
Li, S., Zhu, X., Liu, Y.-Y., & Chen, M. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123800 · Cited by 4
The Significance of STAT3 in Colonic Diseases: A Comprehensive Study of Pathological Roles and Therapeutic Implications
Ahmed, A. T., Oghenemaro, E. F., Hjazi, A., Jain, V. D., Ahmad, I., Roopashree, R., Soothwal, P. K., Goswami, M., Zwamel, A. H., & Kdhim, K. (2025) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-025-01816-0 · Cited by 4
Combined therapeutic effect of YHO-1701 with PD-1 blockade is dependent on natural killer cell activity in syngeneic mouse models
Takahashi, H., Miyoshi, N., Murakami, H., Okamura, Y., Ogo, N., Takagi, A., Muraoka, D., & Asai, A. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03440-4 · Cited by 4
The PAR-score based on PANoptosis genes predicts the progression of ulcerative colitis and the response to anti-TNF-α treatment
Li, Y., Yin, X., Shi, Z., Zhao, Y. L., & Zhong, X. (2025) · Genes & Genomics · doi:10.1007/s13258-025-01675-2 · Cited by 3
Antioxidant and Immunoprotective Effects of Moroccan Honey, Bee Pollen, and Propolis Against Cyclophosphamide‐Induced Immunosuppression in Mice: In Vitro, In Vivo, and In Silico Insights
El-Yagoubi, K., Ouassete, M. E., Soulo, N., Aouji, M., Touzani, S., & Lyoussi, B. (2026) · Journal of Food Science · doi:10.1111/1750-3841.70877 · Cited by 3
Combination of STAT3 inhibitor with Herceptin reduced immune checkpoints expression and provoked anti‐breast cancer immunity: An in vitro study
Jahangiri, A., Ezzeddini, R., Kermani, N. Z., Bahrami, F., & Farrokhi, A. S. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13300 · Cited by 3
MicroRNA-135b mainly functions as an oncogene during tumor progression
Ghasaban, F. T., Taghehchian, N., Zangouei, A. S., Keivany, M. R., & Moghbeli, M. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155547 · Cited by 4
Pan-cancer analysis of STAT3 indicates its potential prognostic value and correlation with immune cell infiltration in prostate cancer
Tuo, Z., Zhang, H., He, K., Jiang, Z., Jiang, C., Chen, X., & Yuan, H. (2024) · Discover Oncology · doi:10.1007/s12672-024-01527-7 · Cited by 3
RNA drugs and nonviral nanocarriers in oncology – present status and emerging concepts
Aigner, A. M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152512 · Cited by 3
B7H6 silencing increases chemosensitivity to dacarbazine and suppresses cell survival and migration in cutaneous melanoma
Mohammadi, A., Najafi, S., Amini, M. A., Baradaran, B., & Firouzamandi, M. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000890 · Cited by 3
Nuclear expression of pSTAT3Tyr705 and pSTAT3Ser727 in the stromal compartment of localized hormone-naïve prostate cancer
Marginean, F. E., Hellsten, R., Krzyzanowska, A., & Bjartell, A. S. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153811 · Cited by 3

Authors: Rébé, C., & Ghiringhelli, F.
Affiliations: Inserm (FR)
Corresponding author: Rébé, Cédric
Ghiringhelli, François
ORCID: Rébé, Cédric
Ghiringhelli, François
Venue: Cancers
Publisher: MDPI AG
Published: 2019-08-30
Volume: 11
Issue: 9
Pages: 1280
ISSN: 2072-6694 (ISSN-L)
DOI: 10.3390/cancers11091280
PMC: PMC6770459
OpenAlex: W2970221585
Cited by: 129
References: 203
Citations by year: 2026: 13 · 2025: 22 · 2024: 29 · 2023: 17 · 2022: 14 · 2021: 13 · 2020: 16 · 2019: 5
FWCI: 1.17
Type: journal article
Language: en
Open access: gold
dx.doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Cancers (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: Ligue Contre le Cancer (Equipe labélisée)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: STAT3, tumor immune microenvironment, antitumor immunity, transcription factors, immune cell activation, myeloid cells, lymphoid cells, STAT3 phosphorylation, STAT3 acetylation, immune checkpoint, tumor progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

STAT3, a Master Regulator of Anti-Tumor Immune Response

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks